Targeted Spontaneous Reporting of Suspected Renal Toxicity in Patients Undergoing Highly Active Anti-Retroviral Therapy in Two Public Health Facilities in Uganda

Drug Safety

Volumn 38, Issue 4, 2015, Pages 395-408

  Ndagije, Helen ^a   Nambasa, Victoria ^a   Namagala, Elizabeth ^b   Nassali, Huldah ^a   Kajungu, Dan ^c   Sematiko, Gordon ^a   Olsson, Sten ^d   Pal, Shanthi ^d  

^a National Drug Authority   (Uganda)

^b MINISTRY OF HEALTH   (Uganda)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHILD; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; INFANT; KIDNEY DISEASE; MALE; MIDDLE AGED; PILOT STUDY; PRESCHOOL CHILD; UGANDA; VERY ELDERLY; YOUNG ADULT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; KIDNEY DISEASES; MALE; MIDDLE AGED; PHARMACOVIGILANCE; PILOT PROJECTS; UGANDA; YOUNG ADULT;

EID: 84939970315     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0277-9     Document Type: Article

References (29)

1. Government of Uganda, Ministry of Health. 2010. Health sector strategic plan III 2010/11-2014/15. http://www.health.go.ug/docs/HSSP_III_2010.pdf. Accessed 28 Oct 2014.
2. Government of Uganda, Ministry of Health, December 2008. Access to and use of medicines by households in Uganda: report of a survey conducted 2008. http://www.afro.who.int/en/downloads/doc_download/5722-uganda-access-to-and-use-of-medecines-by-households.html. Accessed 26 Dec 2014.
3. WHO Collaborating Centre for International Drug Monitoring, Reporting trends. Uppsala, Sweden. Updated 2014 Nov 25. http://who-umc.org/graphics/28351.gif. Accessed 30 Dec 2014.
4. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409–19.
5. Aagaard L, Strandell J, Melskens L, Petersen PSG, Hansen EH. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™. Drug Saf. 2012;35(12):1171–82.
6. Kiguba R, Karamagi C, Waako P, Ndagije HB, Bird SM. Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants. BMJ Open. 2014;4(11):e005869.
7. Lazarou J, Pomeranz B, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.
8. Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109(2):87–94.
9. Hazell L, Shakir SA. Under reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.
10. WHO Collaborating Centre for International Drug Monitoring, VigiLyze, Search and Analyse VigiBase, The WHO Global Database of Individual Case Safety Reports (ICSRs). Uppsala, Sweden. Updated 2014 Dec 11. https://vigilyze.who-umc.org. Accessed 30 Dec 2014.
11. Uganda Bureau of Statistics, 2014 Census Population [Internet]. Kampala; p. 6. Available from: http://unstats.un.org/unsd/demographic/sources/census/2010_PHC/Uganda/UGA-2014-11.pdf. Accessed 26 Dec 2014.
12. Strengthening Pharmaceutical Systems (SPS) Program. Safety of medicine in sub-Saharan Africa: assessment of pharma-covigilance systems and their performance. Submitted to the US Agency for International Development by the Strengthening Pharmaceutical Systems (SPS) Program. Arlington: Management Sciences for Health; 2011. http://apps.who.int/medicinedocs/documents/s19152en/s19152en.pdf. Accessed 26 Dec 2014.
13. Uganda STD/AIDS Control Programme. HIV and AIDS Uganda country progress report; 2013. Kampala; 2014. http://www.unaids.org/sites/default/files/country/documents/UGA_narrative_report2014.pdf. Accessed 26 Dec 2014.
14. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75–81.
15. Chua AC, Llorin RM, Lai K, Cavailler P, Law H. Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort. AIDS Res Ther. 2012;9(1):19.
16. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
17. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505.
18. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS. 2008;22(14):1821–7.
19. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sánchez De La Rosa R, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother. 2006;50(11):3824–32.
20. Ministry of Health, Uganda. The Integrated National Guidelines on Antiretroviral Therapy, Prevention of mother to child transmission of HIV and infant & young child feeding. 1st ed. Kampala; 2011. http://www.emtct-iatt.org/wp-content/uploads/2014/05/GL_Integrated-National-Guidelines-on-ART-PMTCT-and-IYCF-June-2011-MOH-Uganda_0.pdf. Accessed 16 Feb 2015.
21. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22(2):99–103.
22. Romo FT, Aziz M, Livak B, Huesgen E, Colton B, et al. Renal function recovery and HIV viral suppression following tenofovir discontinuation for renal impairment. J AIDS Clin Res. 2014;5:379. doi:10.4172/2155-6113.1000379.
23. Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19(1):1–10.
24. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
25. Europeans Medicines Agency. Tenofovir summary of product characteristics. 2002. p. 1–183. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000419/WC500051737.pdf. Accessed 8 Jan 2015.
26. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773–80.
27. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–75.
28. Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, et al. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother. 2008;62(1):6–11.
29. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37(4):1489–95.